PCV15 and PCV20 Now Available Through VFAAR
PCV15 and PCV20 Now Available Through VFAAR
Vaxneuvance (15-valent pneumococcal conjugate vaccine, PCV15) and Prevnar 20 (20-valent pneumococcal conjugate vaccine, PCV20) are now available through the Vaccines for Adults at Risk (VFAAR) program in line with the updated ACIP recommendations.
Review our announcement and FAQ document to plan your site’s transition to the new vaccines.
VFAAR sites must decide whether they will order PCV20 or PCV15 and PPV23 going forward. Complete the below survey to notify our program of your site’s preference. We will review each site’s submission and reach out with next steps.
We recommend that sites that are part of a system or are affiliated use the same vaccine presentations across sites to ensure continuity of care and help prevent administration errors.
Updated Pneumococcal Vaccine Recommendations
Adults aged ≥ 65 years. Adults aged ≥65 years who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of Pnuemovax 23 (PPSV23) at least one year later.
Adults aged 19–64 years with certain underlying medical conditions or other risk factors. Adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of PPSV23 at least one year later.
PCV13 is no longer recommended for adults under the new recommendations. Providers should no longer administer PCV13 to individuals 19 years of age and older.
Additional Resources
Vaccine Information Statement (February 2022)
Morbidity and Mortality Weekly Report (January 2022)
Thank you for keeping Philadelphia safe and healthy. If you have any questions, please email vaccines@phila.gov.